Highlights

  • Second quarter net Revenue was USD 7.9 million against USD 11.0 million.
  • The net loss was USD 9.0 million against Net Income of USD 10.6 thousand.
  • Gross profit fell 53% to USD 4.8 million for the quarter.
  • Cash and cash equivalents were USD 7.0 million as of June 30, 2026.

BioStem Technologies, Inc. (NASDAQ:BSEM) shares were trading near their 52-week low at USD 1.06 on November 6, 2026, up 1.93% on the day. The company reported second quarter net revenue of USD 7.9 million against USD 11.0 million, and a net loss of USD 9.0 million against net income of USD 10.6 thousand.

BioStem has a market Capitalization of about USD 19.79 million at the current price. It had 17,849,471 shares of common stock outstanding as of August 12, 2026.

Second Quarter Results

Gross profit was USD 4.8 million against USD 10.3 million, a decrease of USD 5.4 million, or 53%. Total operating expenses rose to USD 13.2 million from USD 10.2 million, and the loss from operations was USD 8.4 million against income from operations of USD 112.8 thousand. Loss per share was USD 0.52 against USD 0.00.

First Half Results

Net revenue was USD 14.0 million against USD 26.9 million. Gross Profit was USD 8.6 million against USD 25.4 million, a decrease of USD 16.8 million, or 66%. Total operating expenses were USD 25.9 million against USD 20.0 million, and the loss from operations was USD 17.3 million against income from operations of USD 5.4 million. The net loss was USD 17.8 million against net income of USD 3.9 million, or a loss of USD 1.04 per share against Earnings of USD 0.23.

BioTissue Acquisition

On January 21, 2026, the company completed the Acquisition of the surgical and wound care Business of BioTissue Holdings Inc. and BioTissue Surgical Inc. under an Asset Purchase Agreement. The Assets include the Neox and Clarix product lines, a national footprint of direct sales representatives and contracted independent sales agents, licensed intellectual property and a customer list. The acquired business generated USD 6.7 million of net revenue in the second quarter and USD 12.1 million from the acquisition date through June 30, 2026.

Balance Sheet and Cash Flow

Cash and cash equivalents were USD 7.0 million against USD 29.5 million at the end of 2025. Total assets were USD 48.8 million, total liabilities were USD 21.2 million and stockholders' Equity was USD 27.6 million. Net cash used in Operating Activities was USD 6.4 million against net cash provided of USD 9.5 million, and net cash used in financing activities was USD 1.1 million. The accumulated Deficit was USD 39.0 million.